^
Association details:
| Biomarker: | Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
Published date:
02/08/2022
Excerpt:
Case 2 was a 35-year-old man. BM morphology and immunophenotyping identified AML. The karyotype was 46,XY,t(8;21)(q22;q22) (7), and AML1-ETO and KIT exon 17 mutations were detected...As in case 1, one cycle of venetoclax+midostaurin regimen was given, and the patient achieved a morphologic leukemia-free state (MLFS) after 3 weeks of treatment with<5% blasts in the BM.
DOI:
https://doi.org/10.3389/fonc.2022.841276
